Methylpiperidino pyrazole (Synonyms: MPP) |
Katalog-Nr.GC17161
One-Click Copy Product Info
|
Methylpiperidino pyrazole is a highly selective estrogen receptor α (Erα) antagonist with an IC50 value of 20.01nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 289726-02-9
Sample solution is provided at 25 µL, 10mM.
Methylpiperidino pyrazole is a highly selective estrogen receptor α (Erα) antagonist with an IC50 value of 20.01nM[1]. Methylpiperidino pyrazole binds selectively to ESR1 rather than ESR2 and exhibits both agonistic and antagonistic actions in cultured target cells of uterine origin as well as in the uteri of mice[2]. Methylpiperidino pyrazole also has the ability to attenuate osteoblast maturation[3].
In vitro, MCF-7 cells pretreated with Methylpiperidino pyrazole (100nM) for 30 minutes completely inhibited cell proliferation induced by bisphenol S (BPS) (10μM; 72h) and specifically suppressed the increase of S phase induced by BPS[4]. The treatment of glioblastoma (GBM) cells with Methylpiperidino pyrazole at a concentration of 1μM for a duration of 2 hours effectively blocked the ability of estradiol (E2) to enhance the migration and invasion capabilities of these GBM cells[5].
In vivo, intraperitoneal injection of E2 (0.5μg/gbw) in male adult pompano fish was significantly attenuated in the up-regulation of Erα, estrogen receptors β2 (Erβ2), vitellogenin-B (vtg-B), and vtg-C by Methylpiperidino pyrazole, which also promoted the expressions of erβ1 and vtg-A[6]. Ovariectomized wild-type (WT) and estrogen receptor-β knockout (ERβKO) CF1 mice were treated with Methylpiperidino pyrazole (25, 50, 100, or 150mg; i.p.), which significantly increased uterine weight and cell proliferation[7].
References:
[1] Karaboğa Arslan AK, Yerer MB. α-Chaconine and α-Solanine Inhibit RL95-2 Endometrium Cancer Cell Proliferation by Reducing Expression of Akt (Ser473) and ERα (Ser167). Nutrients. 2018;10(6):672.
[2] Davis AM, Mao J, Naz B, Kohl JA, Rosenfeld CS. Comparative effects of estradiol, methyl-piperidino-pyrazole, raloxifene, and ICI 182 780 on gene expression in the murine uterus. J Mol Endocrinol. 2008;41(4):205-217.
[3] Rodriguez-Merchan, E.C. The importance of smoking in orthopedic surgery. Hosp. Pract. 2018, 46, 175–182.
[4] Lin Z, Zhang X, Zhao F, Ru S. Bisphenol S promotes the cell cycle progression and cell proliferation through ERα-cyclin D-CDK4/6-pRb pathway in MCF-7 breast cancer cells. Toxicol Appl Pharmacol. 2019;366:75-82.
[5] Hernández-Vega AM, Del Moral-Morales A, Zamora-Sánchez CJ, Piña-Medina AG, González-Arenas A, Camacho-Arroyo I. Estradiol Induces Epithelial to Mesenchymal Transition of Human Glioblastoma Cells. Cells. 2020;9(9):1930.
[6] Li X, Brighton Ndandala C, Zhou Q, Huang C, Li G, Chen H. Molecular cloning of estrogen receptor and its function on vitellogenesis in pompano (Trachinotus ovatus). Gen Comp Endocrinol. 2024;346:114403.
[7] Davis AM, Ellersieck MR, Grimm KM, Rosenfeld CS. The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus. Mol Reprod Dev. 2006;73(8):1034-1044.
| Cell experiment [1]: | |
Cell lines | MCF-7 cells |
Preparation Method | MCF-7 cells were pretreated for 30min with selective inhibitors, Methylpiperidino pyrazole (100nM) for estrogen receptor alpha (Erα), and then treated with 10μM bisphenol S (BPS) for 72h, and subjected to CCK8 assay. |
Reaction Conditions | 100nM; 30min |
Applications | 10μM BPS significantly increased cell proliferation, and 100nM Methylpiperidino pyrazole completely inhibited the cell proliferation induced by BPS. Consistent with the inhibition of cell proliferation results, BPS significantly increased the percentage of S phase, and 100nM Methylpiperidino pyrazole specifically suppressed the increase of S phase induced by BPS. |
| Animal experiment [2]: | |
Animal models | CF1 mice |
Preparation Method | The mice were ovariectomized at 7-9 weeks of age. One week after the surgery, CF1 mice were intritoneaperally injected with Methylpiperidino pyrazole at doses of 25mg (n=3), 50mg (n=11), 100mg (n=5), or 150mg (n=3), or with vehicle alone (n=20). On the third day, the mice were humanely euthanized by CO2 inhalation. The uterus was then collected, weighed, and fixed in 10% neutral buffered formalin (NBF). |
Dosage form | 25, 50, 100, or 150mg; i.p. |
Applications | Treatment of ovariectomized mice with 25, 50, or 100mg of Methylpiperidino pyrazole significantly increased the average uterine wet weight-to-body weight ratio. A dose of 150mg of Methylpiperidino pyrazole resulted in a decrease in the average uterine wet weight-to-body weight ratio. Ovariectomized mice treated with Methylpiperidino pyrazole also exhibited increased proliferation, as evidenced by an increase in Ki67-positive staining in the endometrial cells. |
References: | |
| Cas No. | 289726-02-9 | SDF | |
| Überlieferungen | MPP | ||
| Chemical Name | 4-[1-(4-hydroxyphenyl)-4-methyl-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-1H-pyrazol-3-yl]-phenol | ||
| Canonical SMILES | CC1=C(C2=CC=C(OCCN3CCCCC3)C=C2)N(C4=CC=C(O)C=C4)N=C1C5=CC=C(O)C=C5 | ||
| Formula | C29H31N3O3 | M.Wt | 469.6 |
| Löslichkeit | ≤3mg/ml in ethanol;5mg/ml in DMSO;14mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1295 mL | 10.6474 mL | 21.2947 mL |
| 5 mM | 425.9 μL | 2.1295 mL | 4.2589 mL |
| 10 mM | 212.9 μL | 1.0647 mL | 2.1295 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)